15448-76-7

Basic information

• Product Name: DiMethyl bicyclo[2.2.1]heptane-1,4-carboxylate
• Synonyms: DiMethyl bicyclo[2.2.1]heptane-1,4-carboxylate;bicyclo[2.2.1]heptane-1,4-dicarboxylate;Bicyclo[2.2.1]heptane-1,4-dicarboxylic acid, 1,4-dimethyl ester;1,4-dimethyl bicyclo[2.2.1]heptane-1,4-dicarboxylate
• CAS NO: 15448-76-7
• Molecular Formula: C₁₁H₁₆O₄
• Molecular Weight: 212.25
• Mol File: 15448-76-7.mol

Chemical Properties

• Boiling Point: 264.9±13.0 °C(Predicted)
• Appearance: /
• Density: 1.248±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: DiMethyl bicyclo[2.2.1]heptane-1,4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: DiMethyl bicyclo[2.2.1]heptane-1,4-carboxylate(15448-76-7)
• EPA Substance Registry System: DiMethyl bicyclo[2.2.1]heptane-1,4-carboxylate(15448-76-7)

Safety Data

• Hazardous Substances Data: 15448-76-7(Hazardous Substances Data)

Usage

Uses

Used in the Fragrance Industry:
DiMethyl bicyclo[2.2.1]heptane-1,4-carboxylate is used as a fragrance ingredient for its pleasant and fruity scent, contributing to the overall appeal of perfumes and scented products.
Used in the Flavor Industry:
DiMethyl bicyclo[2.2.1]heptane-1,4-carboxylate is used as a flavoring agent in various food and beverage products, enhancing their taste with its sweet and fruity notes.
Regulation and Safety:
DiMethyl bicyclo[2.2.1]heptane-1,4-carboxylate is considered safe for use in consumer products. Its safety and proper usage are regulated by various government agencies to ensure consumer protection and compliance with industry standards.

Upstream product

• 107-04-0 1-Bromo-2-chloroethane 
• 84545-00-6 3-(methoxycarbonyl)-cyclopentane-1-carboxylic acid 
• 343949-04-2 dimethyl cycloheptane-1,3-dicarboxylate 
• 498-66-8 norborn-2-ene 
• 4056-78-4 cyclopentane-1,3-dicarboxylic acid 
• 39590-04-0 (1R,3S)-dimethyl cyclopentane-1,3-dicarboxylate 
• 2435-36-1 cyclopentane?1,3?dimethyl formate 
• 106004-07-3 dimethyl-1-(2'-chloroethyl)cyclopentane-1,3-dicarboxylate 

Downstream Products

• 15544-51-1 bicyclo<2.2.1>heptane-1,4-dicarboxylic acid 
• 15448-77-8 4-carbomethoxybicyclo<2.2.1>heptane-1-carboxylic acid 
• 1350821-89-4 4-(fluoromethyl)-N-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-N-(pyridin-2-yl)bicyclo[2.2.1]heptane-1-carboxamide 
• 1350821-94-1 4-(fluoromethyl)-N-(2-(4-(2-hydroxyphenyl)piperazin-1-yl)ethyl)-N-(pyridin-2-yl)bicyclo[2.2.1]heptane-1-carboxamide 
• 1252672-36-8 4-(benzyloxycarbonylamino)bicyclo[2.2.1]heptane-1-carboxylic acid 
• 737693-57-1 4-aminobicyclo[2.2.1]heptane-1-carboxylic acid 
• 1403865-38-2 benzyl 4-hydroxybicyclo[2.2.1]heptan-1-ylcarbamate 
• 1818847-46-9 bicyclo[2.2.1]heptane-1,4-diamine dihydrochloride 
• 1252672-35-7 4-(benzyloxycarbonylamino)bicyclo[2.2.1]heptane-1-carboxylic acid methyl ester 
• 1252672-39-1 benzyl 4-(hydroxymethyl)bicyclo[2.2.1]heptan-1-ylcarbamate 
• 1201186-85-7 methyl 4-((tert-butoxycarbonyl)amino)bicyclo[2.2.1]heptane-1-carboxylate 
• 1201186-86-8 4-((tert-butoxycarbonyl)amino)bicyclo[2.2.1]heptane-1-carboxylic acid 

Relevant articles and documents

Synthesis and properties of cyclic diester based aliphatic copolyesters

Melt polycondensation was used to prepare a systematic series of random and amorphous copolyesters using the following cycloaliphatic diesters: dimethyl-1,4-cyclohexane dicarboxylate (DMCD), dimethyl bicyclo[2.2.1]heptane-1, 4-dicarboxylate (DMCD-1 ), dimethyl bicyclo[2.2.2]octane-1,4-dicarboxylate (DMCD-2), dimethyl bicyclo[3.2.2]nonane-1,5-dicarboxylate (DMCD-3), 1,4-dimethoxycarbonyl-1,4-dimethylcyclohexane (DMCD-M) and the aliphatic diols: ethylene glycol (EG) and 1,4cyclohexane dimethanol (CHDM). The polymer compositions were determined by nuclear magnetic resonance (NMR) and the molecular weights were determined using size exclusion chromatography (SEC). The polyesters were characterized by dynamic mechanical analysis (DMA), differential scanning calo-rimetry (DSC), and thermogravimetric analysis (TGA). The copolyester based on DMCD-2 was observed to have a higher glass transition temperature (Tg up to 115 °C) than the other copolyesters of this study. For poly[x(DMCD-2)y(DMCD) 30(EG)70(CHDM)], T g increases linearly with increase of DMCD2 mole content. DMA showed that all of the cycloaliphatic copolyesters have secondary relaxations, resulting from the conformational transitions of the cyclohexylene rings.

SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is: (i) halo, cyano, hydroxyl, NRxRx, C(O)OH, C(O)NH2, C1-6 alkyl substituted with zero to 6 R1a, or P(O)R1cR1c; or (ii) L R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R1a, R1c, R2, R3a, R3b, Rx, L, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

SMALL MOLECULE INHIBITORS OF THE JAK FAMILY OF KINASES

2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK.

Small Molecule Inhibitors of the JAK Family of Kinases

2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.

IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES

2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.

BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS

Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, or their use in therapy.

TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS

Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, or their use in therapy.

SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS

Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.

SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.

NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF

The present invention relates to inhibitors of 11-β-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.